Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19.

"Disclosure of potential conflict of interest: D. W. Bates consults for EarlySense, which makes patient safety monitoring systems; receives cash compensation from CDI (Negev), Ltd, which is a not-for-profit incubator for health IT startups; receives equity from ValeraHealth, which makes software to help patients with chronic diseases, Clew, which makes software to support clinical decision making in intensive care, MDClone, which takes clinical data and produces deidentified versions of it, and AESOP, which makes software to reduce medication error rates; and will be receiving research funding from IBM Watson Health. These financial interests have been reviewed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their institutional policies. J. A. Boyce reports consultant work for Sanofi and sits on the Scientific Advisory Board for Siolta Therapeutics and Sanofi-Aventis. The rest of the authors declare that they have no relevant conflicts of interest."

"L.W., D.W.B., and L.Z. are supported by the 10.13039/100000002National Institutes of Health (NIH)-10.13039/100000060National Institute of Allergy and Infectious Diseases (NIAID) (grant no. R01AI150295) and the 10.13039/100000133Agency for Healthcare Research and Quality (grant no. R01HS025375). D.F. is supported by the 10.13039/100000002NIH (grant no. T32AI007306). J.A.B. is supported by the NIH-NIAID (grant nos. R01AI078908, R01AI136041, R37AI052353, and U19AI095219) and the 10.13039/100000050NIH-National Heart, Lung, and Blood Institute (grant no. R01HL117945)."